Drug Profile
GX G6
Alternative Names: GLP1-hyFc; GX-G6; HyGlutide; Long-acting glucagon-like peptide-1 - Genexine; Recombinant-GLP1-fusion-protein; Recombinant-glucagon-like-peptide-1-fusion-protein; TG 103; TJ 103Latest Information Update: 20 Feb 2024
Price :
$50
*
At a glance
- Originator Genexine
- Developer CSPC Pharma; Genexine
- Class Antihyperglycaemics; Glucagon-like peptides; Hormones; Recombinant fusion proteins
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 14 Feb 2024 CSPC Baike (Shandong) Biopharmaceutical plans phase-III trial for Type-2 diabetes mellitus (Monotherapy, In adults, In the elderly) in March 2024 (SC, injection) (NCT06258148)
- 31 Jan 2024 CSPC Baike (Shandong) Biopharmaceutical plans to initiate a phase III trial for Type 2 Diabetes Mellitus (In combination therapy) in China (SC) in March 2024 (NCT06235086)
- 26 Jan 2024 CSPC Pharma plans a phase II trial for Obesity (SC) in January 2024 (NCT06226090)